5 results about "Blood glucose increased" patented technology

The invention relates to the technical field of diabetic health management, in particular to a diabetic health data management system based on a cloud platform. Obtaining a blood sugar amplification factor according to the blood sugar of the patient; correcting the blood glucose amplification factor according to the metabolic equivalent value and the kinetic energy consumption value of the patient to obtain a blood glucose amplification correction factor; obtaining a blood sugar change characteristic value according to the blood sugar amplification correction factor and the diet sugar content before and after the patient diets; and according to the blood glucose change characteristic values of the patient and other patients in the same kind of patient set, obtaining a blood glucose abnormality amplification index. The method comprises the following steps: acquiring a relative abnormal index according to different characteristics of blood glucose of a patient and other patients in the same kind of patient set and a blood glucose abnormal amplification index of the patient; according to the relative anomaly index of the patient, the health management cloud platform is assisted to make medication and diet suggestions for the patient, so that the evaluation accuracy of the cloud platform on the diabetes symptom of the patient is improved, and the possibility of symptom deterioration is reduced.

The invention discloses lactobacillus rhamnosus capable of reducing blood sugar and blood fat and application of the lactobacillus rhamnosus. The lactobacillus rhamnosus CU262 strain provided by the invention is preserved in the Guangdong Microbial Culture Collection Center on March 17, 2025, and the preservation number of the lactobacillus rhamnosus CU262 strain is GDMCC (China General Microbiological Culture Collection Center) No.66018. The lactobacillus rhamnosus CU262 strain provided by the invention has been preserved in the Guangdong Microbial Culture Collection Center on March 17, 2025. Researches show that the CU262 strain has a remarkable inhibition capability on a key enzyme alpha-glucosidase causing blood glucose increase, and the inhibition rate reaches 98% or above; moreover, cholesterol can be efficiently degraded at the same time, the degradation rate reaches 74% or above, and good acid-resistant and cholate-resistant capacity, self-aggregation capacity and oxidation resistance are achieved. The CU262 strain is safe in source, free of side effects, low in price, easy to obtain and easy to prepare. The invention provides more sources and choices for preparing preparations for efficiently inhibiting alpha-glucosidase and degrading cholesterol and hypoglycemic and lipid-lowering products, and provides a new thought for adjuvant therapy of diabetes and obesity.

The application provides a non-invasive blood glucose measurement method, a non-invasive blood glucose measurement system and a medium. The method comprises the following steps: acquiring calibration data of a target object, a real-time blood pressure value and a real-time heart rate value of the target object at a target time; if the target time is in a postprandial period, determining a basic blood pressure set, a basic heart rate set and a reference blood glucose set of the target object changing with time in the postprandial period according to the calibration data; determining a basic blood pressure value, a basic heart rate value and a reference blood glucose set of the target time in the basic blood pressure set, the basic heart rate set and the basic blood glucose set respectively; determining a real-time blood pressure reduction net value according to the real-time blood pressure value, the real-time heart rate value, the basic blood pressure value and the basic heart rate value; converting the real-time blood pressure reduction net value into a real-time blood glucose increase net value according to a preset blood pressure net value and blood glucose net value conversion relationship; and adding the reference blood glucose value and the real-time blood glucose increase net value to obtain a real-time blood glucose value, thereby realizing non-invasive real-time and accurate detection of postprandial blood glucose.

The invention provides a short-time blood glucose prediction method. The method comprises the following steps: acquiring a natural blood glucose sequence, a blood glucose increasing behavior sequence and a blood glucose reducing behavior sequence corresponding to the blood glucose of a patient, the sugar intake behavior of the patient and the active blood glucose reducing behavior of the patient; generating a corresponding natural blood glucose vector, a corresponding glycemic vector and a corresponding hypoglycemic vector according to the sequence; the blood glucose variation under natural blood regulation is obtained by averaging natural blood glucose vectors or performing neural network mapping, and the blood glucose variation caused by the blood glucose rising behaviors is obtained by performing convolution or neural network mapping on the blood glucose rising vectors and the blood glucose rising behavior sequence. Performing convolution or neural network mapping on the hypoglycemic vector and the hypoglycemic behavior sequence to obtain a hypoglycemic change amount caused by the hypoglycemic behavior; summing the blood glucose value at a certain moment with the blood glucose change amount under natural blood regulation and the blood glucose change amount caused by the blood glucose rising behavior and the blood glucose reducing behavior to obtain a blood glucose predicted value at a next moment.

The invention belongs to the technical field of diabetes medicines, and particularly relates to a medicinal and edible composition, solid particles and application of the medicinal and edible composition and the solid particles. Solid particles of the medicinal and edible composition based on the medicinal and edible composition can be used for remarkably improving water intake increase, fasting blood glucose increase, glucose tolerance, insulin resistance, insulin sensitivity, blood fat (TC and TG) levels, liver indexes and liver and pancreas histological morphology levels of mice, so that the symptoms of type 2 diabetes mellitus are remarkably improved.